Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms

Experimental Biology and Medicine

Volumn 240, Issue 7, 2015, Pages 936-945

  Tian, Jihua ^a   Wang, Yanhong ^a   Liu, Xinyan ^a   Zhou, Xiaoshuang ^a   Li, Rongshan ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

cell cycle proteins; IgA nephropathy; mesangial cell; Rapamycin

Indexed keywords

ALBUMIN; CELL CYCLE PROTEIN; CREATININE; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLINE; IMMUNOGLOBULIN A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR B; PROTEIN P27; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ASSAY; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MALE; MESANGIUM CELL; MTT ASSAY; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEINURIA; RAT; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; CELL CYCLE; DISEASE MODEL; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; PATHOLOGY; SPRAGUE DAWLEY RAT;

MAMMALIA; RATTUS;

ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULONEPHRITIS, IGA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MALE; MESANGIAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS;

EID: 84936967028     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214555666     Document Type: Article

References (37)

1. J.V.DonadioJ.P.Grande. IgA nephropathy. N Engl J Med2002; 347(10): 738–48.
2. J.FloegeJ.Feehally. IgA nephropathy: recent developments. J Am Soc Nephrol2000; 11(12): 2395–403.
3. K.N.Lai. Pathogenesis of IgA nephropathy. Nat Rev Nephrol2012; 8(5): 275–283.
4. Y.Kurogi. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev2003; 23(1): 15–31.
5. S.J.Shankland. Cell cycle regulatory proteins in glomerular disease. Kidney Int1999; 56(4): 1208–15.
6. Y.JiangD.W.ChengE.LeviL.P.Singh. IGF-1 increases laminin, cyclin D1, and p21Cip1 expression in glomerular mesangial cells: an investigation of the intracellular signaling pathway and cell-cycle progression. J Cell Biochem2006; 98(1): 208–220.
7. S.J.ShanklandJ.PippinM.FlanaganS.R.CoatsM.NangakuK.L.GordonJ.M.RobertsW.G.CouserR.J.Johnson. Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int1997; 51(4): 1088–1099.
8. M.HidaH.FujitaK.IshikuraS.OmoriM.HoshiyaM.Awazu. Eicosapentaenoic acid inhibits PDGF-induced mitogenesis and cyclin D1 expression via TGF-beta in mesangial cells. J Cell Physiol2003; 196(2): 293–300.
9. T.MonkawaJ.PippinY.YoJ.B.KoppC.E.AlpersS.J.Shankland. The cyclin-dependent kinase inhibitor p21 limits murine mesangial proliferative glomerulonephritis. Nephron Exp Nephrol2006; 102(1): e8–e18.
10. L.Q.QiuR.SinniahS.I.Hsu. Role of differential and cell type-specific expression of cell cycle regulatory proteins in mediating progressive glomerular injury in human IgA nephropathy. Lab Invest2004; 84(9): 1112–25.
11. N.J.Brunskill. Rapamycin: a new string to the antiproteinuric bow?J Am Soc Nephrol2005; 16(7): 1878–79.
12. Y.Liu. Rapamycin and chronic kidney disease: beyond the inhibition of inflammation. Kidney Int2006; 69(11): 1925–27.
13. D.D.SarbassovS.M.AliD.M.Sabatini. Growing roles for the mTOR pathway. Curr Opin Cell Biol2005; 17(6): 596–603.
14. N.HayN.Sonenberg. Upstream and downstream of mTOR. Genes Dev2004; 18(16): 1926–45.
15. D.D.SarbassovS.M.AliD.M.Sabatini. Growing roles for the mTOR pathway. Curr Opin Cell Biol2005; 17(6): 596–603.
16. F.J.DumontQ.Su. Mechanism of action of the immunosuppressant rapamycin. Life Sci1996; 58(5): 373–95.
17. C.EspositoR.ValentinoL.VillaN.SerpieriF.MangioneF.GrosjeanV.EspositoF.CastoldiG.SilenoF.MontagnaN.MaggiM.TorreggianiG.MarchiA.Dal Canton. Effects of sirolimus on human mesangial cells. Transplant Proc2010; 42(4): 1344–46.
18. H.R.LockS.H.SacksM.G.Robson. Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production. Am J Physiol Renal Physiol2007; 292(1): F76–F81.
19. S.KramerY.Wang-RosenkeV.SchollE.BinderT.LoofD.KhadzhynovH.KawachiF.ShimizuF.DiekmannK.BuddeH.H.NeumayerH.Peters. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol2008; 294(2): F440–F449.
20. N.LloberasJ.M.CruzadoM.FranquesaI.Herrero-FresnedaJ.TorrasG.AlperovichI.RamaA.VidalJ.M.Grinyo. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol2006; 17(5): 1395–1404.
21. J.TianY.WangX.ZhouY.LiC.WangJ.LiR.Li. Rapamycin slows IgA nephropathy progression in the rat. Am J Nephrol2014; 39(3): 218–29.
22. Z.KatzirE.LeibovitchH.VakninL.SchreiberE.BergerZ.MatasA.FuxM.BoazA.BriliantA.Biro. Effect of atorvastatin on IgA nephropathy in the rat. Clin Nephrol2013; 79(3): 214–20.
23. K.N.LaiL.Y.ChanH.GuoS.C.TangJ.C.Leung. Additive effect of PPAR-gamma agonist and ARB in treatment of experimental IgA nephropathy. Pediatr Nephrol2011; 26(2): 257–66.
24. N.StoycheffK.PandyaA.OkparaveroA.SchiffA.S.LeveyT.GreeneL.A.Stevens. Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant2011; 26(3): 848–57.
25. J.K.BoydC.K.CheungK.MolyneuxJ.FeehallyJ.Barratt. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int2012; 81(9): 833–43.
26. D.SchlondorffB.Banas. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol2009; 20(6): 1179–87.
27. S.V.GriffinR.PichlerT.WadaM.VaughanR.DurvasulaS.J.Shankland. The role of cell cycle proteins in glomerular disease. Semin Nephrol2003; 23(6): 569–82.
28. G.WolfS.J.Shankland. Cell cycle control in glomerular disease. Prog Cell Cycle Res2003; 5: 71–79.
29. S.J.ShanklandG.Wolf. Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol2000; 278(4): F515–F529.
30. S.J.Shankland. Cell cycle regulatory proteins in glomerular disease. Kidney Int1999; 56(4): 1208–15.
31. A.Cove-SmithB.M.Hendry. The regulation of mesangial cell proliferation. Nephron Exp Nephrol2008; 108(4): e74–e79.
32. R.ZengY.XiongF.ZhuZ.MaW.LiaoY.HeJ.HeW.LiJ.YangQ.LuG.XuY.Yao. Fenofibrate attenuated glucose-induced mesangial cells proliferation and extracellular matrix synthesis via PI3K/AKT and ERK1/2. PLoS ONE2013; 8(10): e76836–e76836.
33. L.H.DongJ.K.WenS.B.MiaoZ.JiaH.J.HuR.H.SunY.WuM.Han. Baicalin inhibits PDGF-BB-stimulated vascular smooth muscle cell proliferation through suppressing PDGFRbeta-ERK signaling and increase in p27 accumulation and prevents injury-induced neointimal hyperplasia. Cell Res2010; 20(11): 1252–62.
34. K.SakakibaraK.KubotaB.WorkuE.J.RyerJ.P.MillerA.KoffK.C.KentB.Liu. PDGF-BB regulates p27 expression through ERK-dependent RNA turn-over in vascular smooth muscle cells. J Biol Chem2005; 280(27): 25470–77.
35. G.WolfR.ReinkingG.ZahnerR.A.StahlS.J.Shankland. Erk 1,2 phosphorylates p27(Kip1): functional evidence for a role in high glucose-induced hypertrophy of mesangial cells. Diabetologia2003; 46(8): 1090–99.
36. M.LeeM.TheodoropoulouJ.GrawF.RoncaroliM.C.ZatelliN.S.Pellegata. Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol Cancer Ther2011; 10(8): 1450–59.
37. S.BurgstallerM.RosnerC.LindengrunM.HannederN.SiegelA.ValliC.FuchsM.Hengstschlager. Tuberin, p27 and mTOR in different cells. Amino Acids2009; 36(2): 297–302.